‘Digital biology is an incredible place to be right now’ – ClearTips
Is working on The intersection of biology and computing may be the most exciting new place for technologists at the moment.
This is the words of Daphne Kollar, Insetro is the founder and chief executive officer – a biotech company that has raised more than $ 243 million in the two years since its launch.
Speaking at our Virtual ClearTips Decision conference, Kollar, a serial entrepreneur who previously co-founded Kaursera And briefly served as chief computing officer for Alphabet Assistant focused on human health, Calico sees digital biology as the next major technological revolution.
“Digital biology is an incredible place to be right now,” Kollar said in an interview.
This is certainly an incredible opportunity for Kollar, whose work now expands the development of treatments for potential neurological diseases and a near-term research and development effort on hepatitis with Guild Pharmaceuticals.
Kolar’s initro It takes its name and inspiration from a combination of two different practices in biological research – in vitro experiments that are performed on living samples in the laboratory and in silico experiments done on computers.
By synthesizing these two disciplines, Kollar’s company flows the process of drug discovery over its head, the company is designed to sift through massive data to discover patterns in the expression of certain conditions. Once those patterns are determined, the company can then investigate the pathways or mechanisms associated with that expression to set targets for potential therapies.
Insitro will then advance the development of novel molecules that can be used to intervene and reverse or prevent the progression of a disease by inhibiting the biological mechanisms associated with it.
“We now have large-scale data that is actually relevant to human disease,” Kollar said. “Machine learning has given us a bunch of tools to really make sense of data.”
The company can identify new patient segments, new interventions, new drugs that can modify the expression of those conditions. “We see ourselves as the first stage of a very long journey using machine learning,” Kollar said.
Take the company’s work on hepatitis in association with Gilead. There, Kollar and his team were able to take a small, high-quality dataset from Gilead’s tests and identify how a disease progressed by looking at patient data from different points in time. Looking at the progress, the company allowed to identify the drivers that facilitate the progression of fibrosis that cause tissue damage. Now the company is using those targets as a starting point for modifiers that can slow the progression of the disease.
Biology, using computers to say it, is used to understand new biotechnology, which is biology in a petri dish, and different models determine the interventions that will make a difference, Kollar said .
“What we’re trying to do is different and how are they different [pharmaceutical] Companies do their work, ”said Kollar. “this isTo shift the trajectory of these companies of hundreds or thousands of people and to shift the culture to a technological culture that is really going to be a challenge. “
This is the main reason that Kolar launched his own company rather than engage in a big pharma play, and it is a classic example of the innovator’s dilemma and the disruptive power of technology laid out in the principles of Clayton Christenson to the Discipline Conference They give their name.
“[It’s] The innovator’s dilemma and the notion of coming up with a mindset that says we are going to do it completely differently, ”said Kollar. “Drug discovery efforts are becoming increasingly expensive and increasingly prone to failure and if we do it in a different way it will enable us to produce better results. “